Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Oxurion NV

OXUR.BR ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

Europe · Healthcare · Biotechnology & Medical Research ·

Belgium Micro Cap Analyst: N/A

Last Close

$0.00

▲ +0.00%

Market Cap $207.10K · Vol 941.00K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$207.10K

Micro Cap

Div Yield

N/A

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

42.86

Momentum

Beta

0.77

vs Market

52W High

$0.01

94.11% below

52W Low

$0.00

33.73% above

Volume

941.00K

Avg 3.56M

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

68.41%

Public shares

Shariah Compliance8 STANDARDS

✗ Oxurion NV (OXUR.BR) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does OXUR.BR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-50.00%

-66.67%

-78.95%

YTD

-88.89%

-93.85%

-99.99%

-100.00%

Financials & Valuation

TTM · Annual

Total Revenue	$651.85K
Net Income	$-4,355,026.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-592.97%
Net Profit Margin	-668.11%
ROE	N/A
ROA · ROIC	-77.69% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	0.36
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	232.00M

Technical Indicators

50-Day SMA	$0.00
200-Day SMA	$0.00
RSI (14)	42.86
Beta	0.77
52-Week High	$0.01
52-Week Low	$0.00

Volume Today	941.00K
Avg Daily Volume (30D)	3.56M
Relative Volume	0.26x
Volatility (10D)	355.05
Volatility (30D)	303.87
Free Float	68.41%

Analyst Consensus

N/A

Current Price $0.00

Mean Target N/A

52W Low$0.00 52W High$0.01

Current

Target

$0.00 $0.01

Current Analyst target

· 0 analysts

Identifiers

ExchangeEurope

FIGIBBG001SPXL53

ISINBE0974487192

CountryBelgium

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.62% ONC BeOne Medicines AG -2.45% 068270.KS Celltrion, Inc. -1.09% MEDP Medpace Holdings, Inc. -0.59% CRL Charles River Laboratories International, Inc. -5.81%

Company Profile

Oxurion NV, formerly known as ThromboGenics NV, is a Belgium-based biopharmaceutical company, which focuses on the development and commercialization of ophthalmic medicines. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The Company is active domestically, as well as operates through offices located in the United States and Ireland.